Clinical trials: Chronic Lymphocytic Leukemia in Relapse
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00014664
- Testing
- apolizumab
- Where
- United States
- Sponsor
- PDL BioPharma, Inc.
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
The purpose of this study is to determine the efficacy of Vismodegib drug in treatment of patients with relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia (CLL).
- Conditions
- Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma, Primary Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- VISMOLY (NCT01944943)
- Testing
- Vismodegib
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- The Lymphoma Academic Research Organisation
B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
The purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's…
- Conditions
- B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT01351935
- Testing
- AVL-292
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Celgene
Leukemia, Lymphoma
Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00058396
- Testing
- lumiliximab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment.
- Conditions
- Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma
- Trial name
- NCT00005803
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine
- Where
- 5 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Fred Hutchinson Cancer Center
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with…
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma)
- Trial name
- NCT01460134
- Testing
- CDX-1127
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Celldex Therapeutics
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Leukemia
Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have chronic…
- Trial name
- NCT00006090
- Testing
- arsenic trioxide
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
This phase II trial is studying how well sunitinib works in treating patients with idiopathic myelofibrosis. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00387426
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
This is an open-label, Phase I/Ib trial with a dose escalation phase, followed by a dose extension phase. The objective of the dose escalation phase is to evaluate the pharmacokinetics (PK) and MTD of P1446A-05 in…
- Trial name
- NCT02117336
- Testing
- P1446A-05
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Piramal Enterprises Limited
Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
This phase Ib/II trial studies the best dose and safety of Bcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib and to see how well they work in treating patients with chronic lymphocytic leukemia that has…
- Trial name
- NCT02427451
- Testing
- Bcl-2 Inhibitor GDC-0199, Obinutuzumab, Ibrutinib
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Kerry Rogers
B-cell Chronic Lymphocytic Leukemia
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to provide early access to Ibrutinib treatment for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and collect additional safety data while the medication is not…
- Trial name
- NCT02437019
- Testing
- PCI-32765 (Ibrutinib)
- Where
- 6 sites in Brazil
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was…
- Trial name
- topMIND (NCT04809467)
- Testing
- tafasitamab, parsaclisib
- Where
- 50 sites in United States, Austria and 5 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients.
- Conditions
- Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent
- Trial name
- NCT03853616
- Testing
- MB-CART19.1
- Where
- 9 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Miltenyi Biomedicine GmbH
Chronic Myeloproliferative Disorders, Leukemia
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant
RATIONALE: Studying immune response to flu vaccine in patients who have undergone a stem cell transplant may help doctors plan the best treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00964821
- Testing
- trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cancer, Chronic Lymphocytic Leukemia (CLL)
A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
This study will collect real-world safety and efficacy data from Japanese relapse/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) participants treated with venetoclax.
- Conditions
- Cancer, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
- Trial name
- VENCLL regPMOS (NCT04198415)
- Where
- 102 sites in Japan
- Volunteers
- 4 people
- Sponsor
- AbbVie
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
RATIONALE: Belinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving belinostat together with bortezomib may kill more cancer cells.
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
- Trial name
- NCT01075425
- Testing
- bortezomib, belinostat, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Virginia Commonwealth University